|Description||Imiglitazar, also known as TAK-559，with hypoglycemic activity it is a non-thiazolidinedione dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist.|
|Synonyms||(4E)-4-[[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl]methoxyimino]-4-phenylbutanoic acid; Imiglitazar; TAK 559; TAK-559; TAK559|
S26948 is a selective PPARγ agonist (EC50 = 8.83 nM). It promotes normal adipocyte differentiation and exhibits a lipid-lowering effect, decreasing the risk of ...
Arhalofenateis, also known as JNJ-39659100 and MBX102, as an uricosuric agent it is a selective, partial PPAR-γ agonist.
T0070907 was identified as a potent and selective PPARgamma antagonist. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte diffe...
GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...
CC-618 has been found to be a PPARβ/δ antagonist that could be used to study the potential biological activity of Cys249 at some extent. IC50: 10 μM.
Troglitazone, PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity, which was approved for the treatment of...
Tesaglitazar is a dual-acting agonist of PPARα/γ (IC50 = 0.35 and 3.8 μM for PPARγ and PPARα, respectively). It reduces insulin resistance in obese Zucker rats ...
Rosiglitazone exhibits insulin-sensitising activity 60- to 200-fold higher than that of troglitazone, englitazone, or piogliazone in rodent models of insulin re...